Vaccine

Arbutus Reports First Quarter 2023 Financial Results and Corporate Update

Additional AB-729 off-treatment data highlighted in an oral presentation at the Global Hepatitis Summit 2023 Dosed first subject in Phase…

3 years ago

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

3 years ago

Vir Biotechnology Receives Expanded Support to Develop Its Novel T Cell Vaccine Platform with New $10 Million Grant for HIV Prevention

– New grant from the Bill & Melinda Gates Foundation supports the Phase 1 development of VIR-1388, an investigational HIV…

3 years ago

Ring Therapeutics Strengthens Executive Team with Appointment of Christopher McNulty as Chief Financial Officer, Head of Corporate Strategy

McNulty brings deep experience in capital formation and business development to Ring Follows recent appointment of Dr. Christopher Wright as…

3 years ago

Elicio Therapeutics to Present Interim Data from the Ongoing Phase 1 Study of Investigational Therapeutic Cancer Vaccine, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancer at ASCO

BOSTON, May 01, 2023 (GLOBE NEWSWIRE) -- Elicio Therapeutics, a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for…

3 years ago

ODAIA Raises $25 Million in Series B Funding to Advance Its AI-Driven Commercial Insights Software for Pharma

With funding, ODAIA to fuel expansion and support the rapid growth of its AI-powered solutions that help pharma companies put…

3 years ago

IN8bio Appoints Jeremy Graff, Ph.D., to Board of Directors

Dr. Jeremy Graff spent 17 years at Eli Lilly and Company, where he built and led the translational oncology group,…

3 years ago

Pathways to Cures are in Sight as MS Canada Hosts Annual Day on the Hill with Carnation Pinning

OTTAWA, May 01, 2023 (GLOBE NEWSWIRE) -- Dozens of representatives of MS Canada are fanning across Ottawa May 1st – May…

3 years ago

Immutep Receives Approval to Initiate INSIGHT-005 Trial Evaluating Eftilagimod Alpha and Anti-PD-L1 Therapy BAVENCIO®

Media Release Investigator-initiated study jointly funded with Merck KGaA, Darmstadt, Germany, will evaluate dual immuno-oncology (IO) combination of eftilagimod alpha…

3 years ago